13F Holdings
中文EN

ZBIO Zenas BioPharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1953926 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-185.3%
TTM EPS YoY-173.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-265.1%
ROA-108.7%
ROIC (approx.)-441.5%
Asset turnover—

Leverage & solvency

Liabilities / assets68.6%
Debt / equity0.00x
Current ratio9.42x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.45x
Accruals ratio-60.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue$10.00M$5.00M$50.00M
R&D expense$168.06M$139.14M$60.03M
SG&A expense$53.32M$29.75M$17.11M
Operating income-$383.06M-$163.89M-$37.15M
Interest expense$7.33M——
Pretax income-$377.82M-$156.56M-$36.82M
Income tax-$79,000$429,000$301,000
Net income-$377.74M-$156.99M-$37.12M
EBITDA-$383.00M-$163.75M-$37.03M
EPS (basic)-8.44-11.89-24.25
EPS (diluted)-8.44-11.89-24.25
Weighted avg. shares (diluted)44.73M13.20M1.53M
Balance sheet
Cash & equivalents$110.64M$319.83M$56.94M
Short-term investments$232.55M$31.02M—
Current assets$351.17M$355.92M$59.80M
PP&E, net$34,000$185,000$193,000
Total assets$383.64M$369.97M$68.18M
Current liabilities$62.65M$57.29M$23.26M
Long-term debt$78.64M——
Total debt$78.64M——
Total liabilities$141.50M$57.51M$43.81M
Shareholders' equity$242.14M$312.46M-$225.72M
Net debt-$32.01M——
Shares outstanding54.49M41.79M1.58M
Cash flow statement
Operating cash flow-$172.33M-$119.67M-$30.53M
Capital expenditure$18,000$131,000$17,000
Free cash flow-$172.35M-$119.81M-$30.55M
Investing cash flow-$251.89M-$30.55M-$17,000
Financing cash flow$215.28M$412.96M$20.12M
Depreciation & amortization$56,000$137,000$113,000
Stock-based compensation$26.35M$10.82M$3.50M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.